441784-83-4

Basic information

• Product Name: 2-((tert-butyl(diphenyl)silyl)oxy)acetic acid ethyl ester
• Synonyms: 2-((tert-butyl(diphenyl)silyl)oxy)acetic acid ethyl ester
• CAS NO: 441784-83-4
• Molecular Weight: 342.51
• Mol File: 441784-83-4.mol

Chemical Properties

• CAS DataBase Reference: 2-((tert-butyl(diphenyl)silyl)oxy)acetic acid ethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 2-((tert-butyl(diphenyl)silyl)oxy)acetic acid ethyl ester(441784-83-4)
• EPA Substance Registry System: 2-((tert-butyl(diphenyl)silyl)oxy)acetic acid ethyl ester(441784-83-4)

Safety Data

• Hazardous Substances Data: 441784-83-4(Hazardous Substances Data)

Usage

Silane compound

Yes, with a tert-butyl motif and a diphenylsilyl moiety

Usage

Commonly used as a reagent in organic synthesis, particularly in the formation of carbon-silicon bonds. Also used in the pharmaceutical industry for the synthesis of various pharmaceutical intermediates, and as a chemical intermediate for the preparation of various organic compounds.

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 58479-61-1 tert-butylchlorodiphenylsilane 
• 18162-48-6 tert-butyldimethylsilyl chloride 

Downstream Products

• 441784-82-3 1-(((tert-butyldiphenylsilyl)oxy)methyl)cyclopropan-1-ol 
• 115869-43-7 (tert-butyldiphenylsilanyloxy)acetaldehyde 
• 1447756-65-1 3-(((Tert-butyldiphenylsilyl)oxy)methyl)isoxazol-5-amine 
• 1447756-66-2 C₂₉H₃₂N₂O₄Si 
• 1447756-64-0 4-((tert-butyldiphenylsilyl)oxy)-3-oxobutanenitrile 
• 441784-90-3 1-({[t-butyl(diphenyl)silyl]oxy}methyl)-2-methylcyclopropanol 
• 441784-84-5 diisopropyl {[1-({[tert-butyl(diphenyl)silyl]oxy}methyl)cyclopropyl]oxy}methylphosphonate 
• 76271-74-4 2-((t-butyldiphenylsilyl)oxy)acetic acid 

Relevant articles and documents

Fullerene derivatives as dual inhibitors of HIV-1 reverse transcriptase and protease

In the present study, we newly synthesized three types of novel fullerene derivatives: pyridinium-type derivatives trans-3a and 4a-5b, piperidinium-type derivative 9, and proline-type derivatives 10a-12. Among the assessed compounds, 5a, 10e, 10f, 10i, 11

SUBSTITUTED IMIDAZOLECARBOXYLATE DERIVATIVES AND THE USE THEREOF

A compound is shown in formula (I). The derivatives of the compound include a stereoisomer, a pharmaceutically acceptable salt, a solvate, a prodrug, a metabolite, a deuterated derivative. The compound is a structurally novel substituted imidazole formate derivative. Substituted imidazole formate derivatives are used in preparing a drug with sedative, hypnotic and/or anesthetic effects, as well as a drug that can control the state of epilepsy. The compound has a good inhibitory effect on the central nervous system, and provides a new option for clinical screening of and/or preparation of a drug with sedative, hypnotic and/or anesthetic effects and controlling the state of epilepsy.

Method for preparing Besifovir

The invention relates to a method for preparing P-[[[1-[(2-amino-9H-purine-9-yl) methyl] cyclopropyl] oxy] methyl]-phosphoric acid (Besifovir). The method comprises the following steps: 1) enabling acompound of formula (1) as shown in the specification to react with tertiary butyl diphenylchlorosilane so as to prepare a compound of formula (2) as shown in the specification; 2) enabling the compound of formula (2) to react with ethyl magnesium bromide so as to prepare a compound of formula (3) as shown in the specification; 3) enabling the compound of the formula (3) to react with p-toluenesulfonyl oxymethyldiethoxyphosphine under a condition that tertiary butanol lithium is adopted as an alkali so as to prepare a compound of formula (23) as shown in the specification; 4) carrying out ammonium fluoride hydrolysis on the compound of formula (23) so as to prepare a compound of formula (24) as shown in the specification; 5) enabling the compound of formula (24) to react with a compound offormula (28) as shown in the specification so as to prepare a compound as a solid of formula (22) as shown in the specification; 6) carrying out reduction dechloridation on the compound of formula (22) as shown in the specification under a condition of a catalyst and a hydrogen supplier so as to prepare a compound as a solid of formula (25) as shown in the specification; 7) carrying out trimethylbromide silane hydrolysis on the compound of formula (25), so as to obtain Besifovir as shown in the specification. The method is cheap in raw material and intermediate material, easy in raw materialand intermediate material obtaining, low in cost, high in yield, gentle in condition and good in security.

NON-FUSED TRICYCLIC COMPOUNDS

Provided herein are compounds and pharmaceutical compositions comprising said compounds that are useful for treating cancers. Specific cancers include those that are mediated by YAP/TAZ or those that are modulated by the interaction between YAP/TAZ and TEAD.

HERBICIDAL ISOXAZOLO[5,4-B]PYRIDINES

The invention relates to isoxazolo[5,4-b]pyridine compounds of formula (I), to the agriculturally useful salts of isoxazolo[5,4-b]pyridine compounds of formula (I), and to their use as herbicides.

Inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and VAP-1 mediated adhesion useful for treatment and prevention of diseases

Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several disorders, including multiple sclerosis and stroke.